OncoMatch/Clinical Trials/NCT05682755
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Is NCT05682755 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Chidamide for leukemia, myeloid, acute.
Treatment: Chidamide — The goal of this phase I/II clinical trial is to test in high-risk acute myeloid leukemia (AML) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • The efficacy and safety of chidamide maintenance therapy in reducing the recurrence rate and GVHD incidence in high-risk AML patients after allo-HSCT. Participants will take oral chidamide (Epidaza) until 180 days after allo-HSCT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Myeloid Leukemia
Demographics
Prior therapy
Must have received: stem cell transplant — allogeneic
Received allo-HSCT and achieved complete remission (CR)
Lab requirements
Blood counts
Hematopoietic reconstitution: neutrophil count ≥ 0.5×10^9/L for 3 consecutive days without G-CSF, platelet count ≥ 20×10^9/L for 7 consecutive days without platelet transfusion, Hb ≥ 80 g/L without red blood cell transfusion; and neutrophil count ≥ 1.5×10^9/L, platelet count ≥ 50×10^9/L within 45 days after transplantation
Kidney function
No serious functional damage to important organs; renal function exclusion
Liver function
No serious functional damage to important organs; decompensated hepatic insufficiency excluded
Cardiac function
No serious functional damage to important organs; myocardial infarction, chronic cardiac insufficiency, and history of prolonged QT syndrome excluded
No serious functional damage to important organs of the body; Serious basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated hepatic insufficiency, renal function, gastrointestinal insufficiency, etc.; History of prolonged QT syndrome
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05682755 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received stem cell transplant.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages